ArticleCureus2025
Comparison of Assisted Reproductive Technology (ART) Outcomes in Two Controlled Ovarian Stimulation Protocols Using Follitropin Delta, a Recombinant Follicle-Stimulating Hormone (rFSH) Injection.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aimed to compare the outcomes of assisted reproductive technology (ART) between progestin-primed ovarian stimulation (PPOS) and antagonist protocols, using follitropin delta as the sole ovarian stimulation agent. While many comparative studies on PPOS and antagonist protocols exist, most utilize follitropin alpha or beta as stimulatory agents. Notably, no studies have reported on the use of follitropin delta in this context. METHODOLOGY: A retrospective analysis was conducted on ART cases initiated in 2022, including 529 PPOS cycles and 298 antagonist cycles. Subgroup analyses were performed based on anti-Müllerian hormone (AMH) levels, dividing patients into four groups: <1.2 ng/mL, 1.2≤ AMH <2.03 ng/mL, 2.03≤ AMH <5.0 ng/mL, and ≥5.0 ng/mL. Assessed outcomes included the number of retrieved oocytes, fertilization rates, cleavage rates, blastocyst formation rates (BL rates), and good-quality blastocyst formation rates (GBL rates), as well as the number of retrieved oocytes, fertilized embryos, cleavage-stage embryos, BL, and GBL. All cases were planned for complete blastocyst vitrification, including those in the antagonist group.
resultsThe mean patient age was 35.1 years in the PPOS group and 36.2 years in the antagonist group. Other baseline characteristics included the causes and duration of infertility, proportion of primary infertility, baseline hormone levels, BMI, duration and dosage of follitropin delta administration, and duration of medroxyprogesterone acetate (MPA) use. There were no significant differences in the background characteristics between the two groups. In AMH levels of 2.03 ng/mL and above, the two groups with AMH-based subgroups showed that the PPOS protocol demonstrated a significantly higher number of retrieved oocytes, BL, and GBL compared to the antagonist protocol.
conclusionWhile previous studies have indicated that no significant differences in outcomes between these protocols, the present study observed that the follitropin delta enhanced the formation of blastocysts and good-quality blastocysts. Further research is needed to determine whether these findings are specific to follitropin delta or extend to other recombinant follicle-stimulating hormone (rFSH) preparations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.